Microsoft, Amazon, Apple, CrowdStrike, Palo Alto Networks and others will use the model as part of a new cybersecurity initiative called Project Glasswing.

The Iran war has hit Amazon data centers in the region, and the company is working around the clock on availability, cloud chief Matt Garman said.

The company is reportedly facing engineering challenges in the development of the foldable phones, which are anticipated to launch later this year.

The Chrysler Pacifica — the brand's last standing model — is expected to grow in sales, according to Chrysler and Dodge CEO Matt McAlear.

Robinhood's U.S. Treasury partnership will help drive emerging investors' exposure to the company, benefiting its future growth, according to Vlad Tenev.

Used car prices rise to highest point since summer 2023

Here are five key things investors need to know to start the trading day.

These are the stocks posting the largest moves in early trading.

CNBC spoke with five U.S. patients who recently started the pill following its launch and have varying initial experiences with the drug.

Broadcom shares rose in premarket trading as the chip designer announced an extension to its deal with Google on Monday.

Proposed U.S. restrictions would target ASML's deep ultraviolet (DUV) lithography machine, which Chinese companies have so far been able to access.

Samsung Electronics forecast record first-quarter operating profit that came in far above analyst estimates on booming demand for AI memory chips.

Broadcom said it agreed to produce future versions of Google artificial intelligence chips, and announced an expanded deal with Anthropic.

The Trump administration will increase average Medicare Advantage payments by 2.48%, or more than $13 billion, in 2027.

OpenAI sent a letter to the California and Delaware attorneys general, urging them to investigate "anti-competitive behavior" by Elon Musk and his associates.

Citrini Research said it dispatched an analyst to Oman's Musandam Peninsula, where he traveled by boat to observe shipping activity firsthand.

A CNBC investigation revealed the proliferation of AFPs, which import prescription drugs from overseas in what U.S. regulators say is a violation of import laws.

Microsoft is likely to see some upside from its push to integrate AI into its 365 offering, according to Goldman Sachs.

These are the stocks posting the largest moves premarket.

Here are five key things investors need to know to start the trading day.

JPMorgan CEO Jamie Dimon in his annual letter to shareholders noted the country's 250th anniversary and called for a broad recommitment to American ideals.

Rapid technological advancements and the huge sums of money flowing into the data center are posing both risks and rewards for insurers.

The transition from wheels to weapons is achievable in part because many of the underlying skills are highly transferable, according to experts.

Rep. Seth Moulton, D-Mass., called the market "DISGUSTING" and said bettors were wagering on whether American troops would be saved.

In dominating consumer devices, Apple sold users on the promise of privacy. To compete in AI, it may have to pivot.

The damage to Oracle's building comes after Iran warned it would target U.S. tech companies operating in the Middle East.

OpenAI President Greg Brockman will oversee product in Simo's absence.

Internet platforms have long been able to rely on special protections to avoid liability for what takes place on their sites. But that may be changing.

Over 10 months after shelling out an eye-popping $6.4 billion for Jony Ive's nascent devices startup, OpenAI announced it's buying media company TBPN.

Funding for defense startups has ballooned in recent years as militaries scramble to modernize.

The Trump administration is preparing to impose new tariffs on drugmakers that have not struck deals with the president to lower their U.S. drug prices.

Blue Owl attributed the higher-than-usual requests to "heightened market concerns around AI-related disruption to software companies."

Novo and Eli Lilly are both trying to shape the narrative of their rival pills, considered to be the start of the next phase of the weight-loss drug era.

These are the stocks posting the largest moves in the premarket.

Stellantis-backed Leapmotor delivered 110,155 new energy vehicles in the first three months of 2026, exceeding 100,000 deliveries for a fourth-straight quarter.

Various car selling platforms have reported a sharp increase in consumer interest for EVs since the Middle East crisis began.

Eli Lilly opposes the White House's push to codify "most favored nation" drug pricing into law, CEO Dave Ricks said in an interview with CNBC.

These are the stocks posting the largest moves in midday trading.

The FDA approval of Eli Lilly's GLP-1 pill Foundayo comes nearly three months after Novo Nordisk's oral version of Wegovy hit the market.

Visa's new tools are part of a larger push by major banks and financial institutions to incorporate AI into their businesses.

These are the stocks posting the largest moves premarket.

Xpeng's deal to make software, hardware and even vehicles with VW Group in China shows that Chinese firms are now making the high-value components.

See which stocks are posting big moves after the bell.

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Mercedes is investing $4 billion in its Alabama plant through 2030 in a push to increase production as the automaker targets a 28% increase in U.S. car sales.

The Berkshire Hathaway chairman said the growing number of nuclear-armed states has fundamentally altered the global risk landscape.

Bank of America data reveals lower-income consumers are already pulling back on spending. Consumer sentiment shows higher earners are feeling less confident.

Centessa is one of several companies working on a new class of drugs to treat narcolepsy, a condition that makes it difficult for people to stay awake.

Apple remains Berkshire Hathaway's largest holding even after the conglomerate trimmed its stake at the end of last year.

Longer subscriptions offer lower monthly pricing, with people expected to save up to $1,200 a year on the injection and as much as $600 a year on the pill.

The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.

Lyme disease is an illness caused by bacteria most commonly spread to humans from ticks. It can cause arthritis, muscle weakness and pain.

Merging the companies is an opportunity in fast-growing nutrition space, said Danone CEO Antoine de Saint-Affrique.

With rising inflation and changing tariff policies, menstrual products have seen a drastic rise in price over the past few years.

For restaurants and food companies, the increasing adoption of GLP-1 drugs present both an opportunity and a threat to their businesses.

Two months after its launch, CNBC's rare disease initiative is starting to reach a broader audience.

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

Many Americans face financial pressures after Affordable Care Act enhanced premium subsidies expired at the end of 2025.

Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and its upcoming pill, orforglipron.

Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.